Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
The optimal duration of checkpoint blockade for responding patients remains unclear. UK's NICE have mandated maximum 2 years of therapy for patients with lung cancer (NSCLC).
https://www.nice.org.uk/guidance/ta600/chapter/1-Recommendations